VH Fragments
Antibody-based therapies have become a major driver for the pharmaceutical industry, addressing many medical needs and yielding $45bn of sales in 2009 with continued annual growth of >20%. This has led to an intense focus on improved platforms for the generation of antibodies, and on next generation antibody-based molecules with potentially improved, more drug-like, properties. Antibody fragments have a key role to play. Several products based on first or second generation antibody fragments (for example Fab and scFv) are marketed or in clinical development. However, VH fragments are the smallest fragments that retain target binding and affinity, and therefore have significant benefits over earlier generations of antibody fragments.
VH Fragments - Smallest Binding Unit
- Local administration
- Greatest flexibility including bi-specifics
- Easy to manufacture and stable
- Can engineer half-life